Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

Completed · Phase 1

Conditions studied: Cancer

In brief

A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).

Key facts

Study ID

NCT00993239

Run by

TetraLogic Pharmaceuticals

People needed

50

Starts

2009-11-01

Expected to finish

2013-03-01

Last updated by the study team

2016-03-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Roswell Park Cancer Institute — Buffalo, New York, United States
• University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.